Literature DB >> 26368117

The Journey to Establish CGRP as a Migraine Target: A Retrospective View.

Lars Edvinsson1.   

Abstract

In this retrospective, Dr. Lars Edvinsson recounts early steps and milestones in our understanding of the neuropeptide calcitonin gene-related peptide (CGRP) in the trigeminovascular system and its role in migraine. The discovery of the presence and function of CGRP and other neuropeptides in the cerebral vasculature and its sensory innervation is described. He relates the seminal finding that CGRP is uniquely released during migraine and the journey to develop blockers of CGRP effects. Now, over 30 years since its discovery, CGRP has become the target for a number of promising novel treatments for migraine patients.
© 2015 American Headache Society.

Entities:  

Keywords:  CGRP; migraine; review

Mesh：

Substances：

Year:  2015        PMID： 26368117     DOI： 10.1111/head.12656

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


  17 in total

1.  Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients.

Authors:  Reza Fekrazad; Ahmadreza Sardarian; Kamran Azma; Masoumeh Karami; Afshin Borhani-Haghighi; Behrouz Gharesi-Fard; Bahram Movahedi
Journal:  Neurol Sci       Date:  2018-04-13       Impact factor: 3.307

2.  Intranasally administered IGF-1 inhibits spreading depression in vivo.

Authors:  Yelena Y Grinberg; Lois A Zitzow; Richard P Kraig
Journal:  Brain Res       Date:  2017-09-23       Impact factor: 3.252

3.  The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel.

Authors:  Silvia Benemei; Francesco De Logu; Simone Li Puma; Ilaria Maddalena Marone; Elisabetta Coppi; Filippo Ugolini; Wolfgang Liedtke; Federica Pollastro; Giovanni Appendino; Pierangelo Geppetti; Serena Materazzi; Romina Nassini
Journal:  Br J Pharmacol       Date:  2017-07-20       Impact factor: 8.739

Review 4.  From LBR-101 to Fremanezumab for Migraine.

Authors:  Marcelo E Bigal; Alan M Rapoport; Stephen D Silberstein; Sarah Walter; Richard J Hargreaves; Ernesto Aycardi
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 5.  The role of anti-CGRP antibodies in the pathophysiology of primary headaches.

Authors:  Piero Barbanti; Cinzia Aurilia; Luisa Fofi; Gabriella Egeo; Patrizia Ferroni
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 6.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 7.  Anti-CGRP monoclonal antibodies in migraine: current perspectives.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Martina Curto; Andrea Negro; Raffaele Costantini; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2016-06-23       Impact factor: 3.397

8.  Translational Block in Stroke: A Constructive and "Out-of-the-Box" Reappraisal.

Authors:  Athanasios Lourbopoulos; Iordanis Mourouzis; Christodoulos Xinaris; Nefeli Zerva; Konstantinos Filippakis; Angelos Pavlopoulos; Constantinos Pantos
Journal:  Front Neurosci       Date:  2021-05-14       Impact factor: 4.677

9.  Characterization of a mouse model of headache.

Authors:  Dongyue Huang; Lynn Ren; Chang-Shen Qiu; Ping Liu; Jonathan Peterson; Yuchio Yanagawa; Yu-Qing Cao
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

10.  Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine.

Authors:  Brandon J Rea; Anne-Sophie Wattiez; Jayme S Waite; William C Castonguay; Chantel M Schmidt; Aaron M Fairbanks; Bennett R Robertson; Cameron J Brown; Bianca N Mason; Maria-Cristina Moldovan-Loomis; Leon F Garcia-Martinez; Pieter Poolman; Johannes Ledolter; Randy H Kardon; Levi P Sowers; Andrew F Russo
Journal:  Pain       Date:  2018-11       Impact factor: 7.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.